Market Place
Sourcing Support
Wave Life Sciences Reports Q1 2026 Financial Results
28 Apr 2026 //
GLOBENEWSWIRE
Wave Life Sciences Sets Q1 2026 Financial Results Release Date
22 Apr 2026 //
GLOBENEWSWIRE
Wave Life Sciences Proposes Redomiciliation to US
15 Apr 2026 //
FIRSTWORD PHARMA
Wave Life Sciences Reports Positive Phase 1 Results For WVE-007
26 Mar 2026 //
GLOBENEWSWIRE
Wave Stock Cut In Half On Underwhelming Higher Dose Obesity Data
26 Mar 2026 //
BIOSPACE
Wave Life Sciences: Late-Breaker Oral on WVE-006 for AATD
05 Mar 2026 //
GLOBENEWSWIRE
Wave Life Sciences at Oppenheimer Life Sciences Conference
23 Feb 2026 //
GLOBENEWSWIRE
Wave Life Sciences Q4 and Full Year 2025 Financial Results
19 Feb 2026 //
GLOBENEWSWIRE
Wave Life Sciences Expedites WVE-006 Regulatory Process
02 Feb 2026 //
GLOBENEWSWIRE
Wave Life Emphasizes 2026 Strategy At J.P. Morgan Conference
12 Jan 2026 //
GLOBENEWSWIRE
Wave Life Sciences To Present At J.P. Morgan Healthcare
05 Jan 2026 //
GLOBENEWSWIRE
Wave Life Sciences Launches $250M Shares, Warrants Offering
08 Dec 2025 //
GLOBENEWSWIRE
Wave Life Sciences Reveals Encouraging Phase 1 INLIGHT Trial
08 Dec 2025 //
GLOBENEWSWIRE
Wave, Structure stocks double on obesity data readouts
08 Dec 2025 //
FIERCE BIOTECH
Wave Life Sciences To Release Phase 1 INLIGHT Trial Interim Data
07 Dec 2025 //
GLOBENEWSWIRE
Wave Life Sciences Reports Q3 2025 Financials & Business Update
10 Nov 2025 //
GLOBENEWSWIRE
Wave Life Sciences To Present At Upcoming Investor Conferences
07 Nov 2025 //
GLOBENEWSWIRE
Wave Life Sciences Showcases WVE-007 Preclinical Data
04 Nov 2025 //
GLOBENEWSWIRE
Wave Life Sciences To Release Q3 2025 Financial Results
04 Nov 2025 //
GLOBENEWSWIRE
Wave Life Sciences Shows Positive WVE-007 Data in Obesity Trial
29 Oct 2025 //
GLOBENEWSWIRE
Wave Life Sciences Hosts Virtual Research Day on October 29
18 Sep 2025 //
GLOBENEWSWIRE
Wave Crashes Despite Successful RNA Editing in AATD Study
05 Sep 2025 //
BIOSPACE
Wave reports AATD win, but investors lukewarm
03 Sep 2025 //
FIERCE BIOTECH
Wave Life Sciences Reports Progress in WVE-006 Trial
03 Sep 2025 //
GLOBENEWSWIRE
Wave Life Sciences Q2 2025 Financial Results and Business Update
30 Jul 2025 //
GLOBENEWSWIRE
Wave Life Sciences to Present at 2025 Healthcare Conference
29 May 2025 //
GLOBENEWSWIRE
Wave Life Sciences Appoints Dr. Christopher Wright as CMO
28 May 2025 //
GLOBENEWSWIRE
Wave Life Sciences Reports Q1 2025 Results and Business Update
08 May 2025 //
GLOBENEWSWIRE
Wave Life Sciences Q1 2025 Financial Results on May 8, 2025
01 May 2025 //
GLOBENEWSWIRE
Wave`s DMD drug remains on track in 48-week data
27 Mar 2025 //
FIERCE PHARMA
Wave Reports Q4, Full-Year 2024 Financial Results, Business Update
04 Mar 2025 //
GLOBENEWSWIRE
Wave Life Sciences 2024 Financial Results Set for March 4, 2025
25 Feb 2025 //
GLOBENEWSWIRE
Wave Life Sciences Launches Phase 1 INLIGHT Trial of WVE-007
06 Feb 2025 //
GLOBENEWSWIRE
Wave Previews 2025 Milestones Ahead Of J.P. Morgan Event
13 Jan 2025 //
GLOBENEWSWIRE
Wave Life Sciences Submits First Trial Application for WVE-007
23 Dec 2024 //
GLOBENEWSWIRE
Wave Life Sciences to Present at J.P. Morgan Healthcare Conf.
16 Dec 2024 //
GLOBENEWSWIRE
Wave Life Sciences to Present at Upcoming Investor Conferences
26 Nov 2024 //
GLOBENEWSWIRE
Wave Life Sciences to Present at Jefferies London Conference
15 Nov 2024 //
GLOBENEWSWIRE
Wave Life Sciences Reports Q3 2024 Financial Results & Update
12 Nov 2024 //
GLOBENEWSWIRE
Wave Life Sciences to Report Q3 2024 Results on Nov 12
04 Nov 2024 //
GLOBENEWSWIRE
Wave Life Sciences Highlights INHBE siRNA for Obesity
30 Oct 2024 //
GLOBENEWSWIRE
Takeda axes Huntington’s pact, freeing Wave to pursue partners
18 Oct 2024 //
FIERCE BIOTECH
Wave Life Announce Virtual Research Day on Wednesday, Oct 30, 2024
16 Oct 2024 //
GLOBENEWSWIRE
Wave Life Achieves 1st RNA Editing In Humans For Alpha-1 Antitrypsin
16 Oct 2024 //
GLOBENEWSWIRE
Wave Life Sciences Closes Upsized Public Offering of Shares
01 Oct 2024 //
GLOBENEWSWIRE
Wave Life Sciences To Present At Chardan Conference
30 Sep 2024 //
GLOBENEWSWIRE
Wave Life Sciences Prices $200 Million Public Offering
25 Sep 2024 //
GLOBENEWSWIRE
Wave Life Sciences Announces Positive Interim Data for WVE-N531
24 Sep 2024 //
GLOBENEWSWIRE
Wave Life Sciences Announces Public Offering of Ordinary Shares
24 Sep 2024 //
GLOBENEWSWIRE
Wave Life Sciences Reports Q2 2024 Results And Business Update
08 Aug 2024 //
GLOBENEWSWIRE
Wave Life Sciences Q2 2024 Results Call Set For August 8
01 Aug 2024 //
GLOBENEWSWIRE
Wave Life: CTA Approval For AATD Gene Therapy Trial RestorAATion-2
30 Apr 2024 //
GLOBENEWSWIRE
Wave Life Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531
15 Dec 2023 //
GLOBENEWSWIRE
Wave Life Highlights Strategy for Building the Leading RNA Medicines Company
28 Sep 2023 //
GLOBENEWSWIRE
Wave Life Announces Submission of First Clinical Trial Application for WVE-006
05 Sep 2023 //
GLOBENEWSWIRE
Wave Life Announces Results from Phase 1b/2a FOCUS-C9 Study of WVE-004
23 May 2023 //
GLOBENEWSWIRE
Wave`s ALS-dementia drug crashes out after early-phase flop
23 May 2023 //
FIERCE BIOTECH
Wave Life Announces Nucleic Acids Research Publication Potential Best-in
20 Apr 2023 //
GLOBENEWSWIRE
